• Oral clonidine hydrochloride is indicated for the treatment of hypertension.
• Transdermal clonidine hydrochloride is indicated for the treatment of hypertension and for the management of symptoms associated with opioid withdrawal.
• Clonidine is also indicated in adjunct with other stimulants to treat attention deficit hyperactivity disorder.

Hypertension (High Blood Pressure)

Opioid Dependence

Attention Deficit Hyperactivity Disorder

• The dosage of clonidine hydrochloride depends on the individual's medical condition, response to treatment, and age.
• Oral clonidine hydrochloride is usually initiated at a low dose of 0.1 mg twice daily, with a maximum recommended dose of 2.4 mg per day.
• Transdermal clonidine hydrochloride patches are available in various strengths, and the appropriate strength and dosing regimen should be determined by the prescribing healthcare provider.
• Clonidine hydrochloride should be taken as directed by the healthcare provider and should not be discontinued without consulting the healthcare provider.

The most common adverse reactions of clonidine hydrochloride include dry mouth, sedation, dizziness, fatigue, constipation, and headache.

Dry Mouth

Sedation

Dizziness

Fatigue

• Clonidine hydrochloride should be used with caution in patients with a history of depression, suicidal ideation, or kidney or liver disease.
• Clonidine hydrochloride may cause drowsiness or dizziness, and patients should avoid driving or operating heavy machinery until they know how the medication affects them.
• Abrupt discontinuation of clonidine hydrochloride may lead to rebound hypertension and should be avoided.
• Patients with a history of heart disease or stroke should be monitored closely while taking clonidine hydrochloride, as the medication can lower blood pressure and heart rate.
• Clonidine hydrochloride should not be used during pregnancy or while breastfeeding unless the benefits outweigh the potential risks.